BALAXI PHARMACEUTICALS
Quarterly Results Analysis [Jun2025]
BALAXI PHARMACEUTICALS Quarterly Results
Consolidated | Jun2025 UnAudited |
Mar2025 Audited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 Audited |
Dec2023 Audited |
Sep2023 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹71 Cr | ₹76 Cr | ₹73 Cr | ₹77 Cr | ₹66 Cr | ₹60 Cr | ₹61 Cr | ₹55 Cr |
Expenses | ₹67 Cr | ₹64 Cr | ₹69 Cr | ₹67 Cr | ₹56 Cr | ₹46 Cr | ₹47 Cr | ₹44 Cr |
Operating Income | ₹4 Cr | ₹13 Cr | ₹4 Cr | ₹11 Cr | ₹10 Cr | ₹13 Cr | ₹14 Cr | ₹11 Cr |
Other Income | ₹-2 Cr | ₹-2 Cr | ₹4 Cr | ₹-4 Cr | ₹-2 Cr | ₹-2 Cr | ₹0 Cr | ₹0 Cr |
Interest | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
Profit Before Tax | ₹1 Cr | ₹10 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹11 Cr | ₹14 Cr | ₹16 Cr |
Profit After Tax | ₹0 Cr | ₹9 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹11 Cr | ₹14 Cr | ₹14 Cr |
EPS | ₹0.05 | ₹1.56 | ₹0.97 | ₹0.83 | ₹1.17 | ₹2.01 | ₹2.66 | ₹2.82 |
Industry Peers & Returns | 1W | 1M | 1Y |
BALAXI PHARMACEUTICALS | -4.4% | -6.4% | -57.1% |
ADANI ENTERPRISES | -4.8% | -10.9% | -25.2% |
REDINGTON | -5.1% | -20.7% | 16.5% |
MMTC | -5% | -7.3% | -38.4% |
HONASA CONSUMER | -0.1% | 12.8% | -36.3% |
LLOYDS ENTERPRISES | -5.7% | -1.4% | 93.3% |
ENTERO HEALTHCARE SOLUTIONS | -2.2% | -0.6% | -5% |
OPTIEMUS INFRACOM | -7% | -1.6% | -3.7% |
POLO QUEEN INDUSTRIAL & FINTECH | 12.1% | -14% | 10.7% |
BALAXI PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -7.24 % |
Y-o-Y | 7.80 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Jun2025 | ₹71 Cr | -7.24 | |
Mar2025 | ₹76 Cr | 4.06 | |
Dec2024 | ₹73 Cr | -5.29 | |
Sep2024 | ₹77 Cr | 17.92 | |
Jun2024 | ₹66 Cr | 9.68 | |
Mar2024 | ₹60 Cr | -1.57 | |
Dec2023 | ₹61 Cr | 11.08 | |
Sep2023 | ₹55 Cr | - |
BALAXI PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -66.96 % |
Y-o-Y | -58.87 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Jun2025 | ₹4 Cr | -66.96 | |
Mar2025 | ₹13 Cr | 214.85 | |
Dec2024 | ₹4 Cr | -62.34 | |
Sep2024 | ₹11 Cr | 4.97 | |
Jun2024 | ₹10 Cr | -25.10 | |
Mar2024 | ₹13 Cr | -1.42 | |
Dec2023 | ₹14 Cr | 26.90 | |
Sep2023 | ₹11 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -64.40 % |
Y-o-Y | -61.87 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Jun2025 | 5.86% | -64.40 | |
Mar2025 | 16.46% | 202.57 | |
Dec2024 | 5.44% | -60.23 | |
Sep2024 | 13.68% | -11.00 | |
Jun2024 | 15.37% | -31.72 | |
Mar2024 | 22.51% | 0.18 | |
Dec2023 | 22.47% | 14.23 | |
Sep2023 | 19.67% | - |
BALAXI PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -96.63 % |
Y-o-Y | -95.51 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Jun2025 | ₹0 Cr | -96.63 | |
Mar2025 | ₹9 Cr | 61.10 | |
Dec2024 | ₹5 Cr | 16.87 | |
Sep2024 | ₹5 Cr | -29.20 | |
Jun2024 | ₹6 Cr | -40.73 | |
Mar2024 | ₹11 Cr | -19.57 | |
Dec2023 | ₹14 Cr | -5.78 | |
Sep2023 | ₹14 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -96.38 % |
Y-o-Y | -95.85 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Jun2025 | 0.41 % | -96.38 | |
Mar2025 | 11.33 % | 54.78 | |
Dec2024 | 7.32 % | 23.44 | |
Sep2024 | 5.93 % | -39.92 | |
Jun2024 | 9.87 % | -45.98 | |
Mar2024 | 18.27 % | -18.29 | |
Dec2023 | 22.36 % | -15.21 | |
Sep2023 | 26.37 % | - |
BALAXI PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -96.79 % |
Y-o-Y | -95.73 % |
Quarters | EPS | % Change | |
---|---|---|---|
Jun2025 | ₹0.05 | -96.79 | |
Mar2025 | ₹1.56 | 60.82 | |
Dec2024 | ₹0.97 | 16.87 | |
Sep2024 | ₹0.83 | -29.06 | |
Jun2024 | ₹1.17 | -41.79 | |
Mar2024 | ₹2.01 | -24.44 | |
Dec2023 | ₹2.66 | -5.67 | |
Sep2023 | ₹2.82 | - |
You may also like the below Video Courses
ADANI ENTERPRISES LTD vs REDINGTON LTD vs MMTC LTD
HONASA CONSUMER LTD vs LLOYDS ENTERPRISES LTD vs ENTERO HEALTHCARE SOLUTIONS LTD